Physician profile
Daniel Evans Huckestein
NPI 1841297819
$3,547.54
in general payments reported to CMS, 2019-2025
29 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $12.53 · 2021: $60.32 · 2022: $563 · 2023: $660 · 2024: $937 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,778.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.06 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $505.49 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $468.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $463.35 | 2022-2025 | |
| Glaxosmithkline, LLC. | $259.43 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $197.34 | 2021-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $161.64 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Indivior INC. | $119.11 | 2024-2025 | Sublocade |
| Exact Sciences Corporation | $98.59 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $76.72 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $68.85 | 2023-2025 | Veozah |
| Lilly USA, LLC | $57.65 | 2022-2025 | Jardiance, Mounjaro |
| Novartis Pharmaceuticals Corporation | $51.53 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $43.57 | 2022-2024 | |
| Tactile Systems Technology INC | $42.71 | 2022-2024 | Entre Plus, Flexitouch Plus |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $37.85 | 2019 | |
| Sumitomo Pharma America, INC. | $34.12 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.28 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $32.11 | 2024 | Voquezna |
| Philips North America LLC | $26.80 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $25.26 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Sunovion Pharmaceuticals INC. | $23.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.49 | 2025 | Jardiance |
| Boston Scientific Corporation | $21.41 | 2025 | Watchman Flx |
| Ultragenyx Pharmaceutical INC. | $16.83 | 2022 | |
| Amarin Pharma, INC. | $14.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.08 | 2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $13.81 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.13 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Huckestein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.